CIRS diagnosis · mold illness screening

CIRS Diagnosis: What the Mold Evidence Supports in Screening

No assay in the CIRS diagnosis framework has a published healthy reference interval standardized across laboratories, so the panel cannot yet be read. What the mold evidence supports is immunologic and infectious disease, with the respiratory effects of damp buildings graded sufficient.

Patients now arrive with a water-damaged building, a stalled recovery and a commercial result in hand. The clinical work is separating the established tiers from the marketed ones, then documenting function objectively.

Requests for a CIRS diagnosis, chronic inflammatory response syndrome attributed to water-damaged buildings, now reach primary care, pain, gastroenterology and allergy clinics, usually after an adherent patient has improved partway and plateaued. The video Mold Illness: Fix the Basement, Skip the Panel, from The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, grades the mold literature by evidence tier. For a screening practice the questions are operational: which parts of the framework hold, which assays cannot be interpreted, what belongs in the chart, and where objective function measurement earns a place.

What is established, and at which tier

The mold-related disease with defined mechanisms is immunologic and infectious: asthma, allergic rhinitis, allergic bronchopulmonary aspergillosis, sinusitis and hypersensitivity pneumonitis. The allergy position paper that set out those mechanisms classed the newer proposed syndromes as largely unproved. The 2004 Institute of Medicine synthesis found sufficient evidence associating damp indoor environments with some upper respiratory symptoms, and American medical toxicology still endorses it. A 2024 multi-society European guideline grades respiratory disease as sufficient, atopic eczema as limited or suspected, and gastrointestinal effects as inadequate or insufficient.

Exposure route is the skeptics’ strongest argument, and it is arithmetic rather than rhetoric. The 2025 American College of Medical Toxicology statement identifies diet as the most important source of human mycotoxin exposure and cites modeling that places the maximum inhaled dose in moldy buildings orders of magnitude below demonstrated thresholds for harm. The same statement reports no documented evidence that indoor fungal or mycotoxin inhalation causes a chronic toxic encephalopathy. Occupational medicine reached the equivalent conclusion in 2003.

The CIRS diagnosis panel, and why it cannot yet be read

Measura [Cardiometabolic and Autonomic Health Analysis] performs none of the framework’s assays: no mycotoxin or mycotoxin antibody testing, no urine toxin panels, no HLA-DR/DQ typing, no alpha-MSH, TGF-beta 1, C4a or MMP-9 profile, and no visual contrast sensitivity testing. Those are different tests run elsewhere. The case definition itself is falsifiable, which is to its credit: reduced regulatory neuropeptides, especially MSH, with elevation of at least one of the three inflammatory markers. Outside the originating group it stands neither falsified nor confirmed.

Alpha-MSH is a genuine anti-inflammatory peptide, but it does not behave like a deficiency marker. It rose in normal subjects given endotoxin, fell in sepsis, was elevated in more advanced HIV disease and in more inflamed synovial fluid, and runs lower in healthy elderly people than in young controls. No reference interval from a healthy population, assay standardization, inter-laboratory comparison or pre-analytic stability data has been published. Among the 28 who consented to the primary cholestyramine trial, 25 had an abnormal MSH and 1 an abnormal IgE, and MSH was not re-measured after treatment.

Urine mycotoxin panels fail on the same missing distribution. There is no FDA-approved urine mycotoxin assay. The federal case report is instructive when each value is read against its own line: ochratoxin returned at 2.8 ppb against that analyte’s cutoff of 2.0 ppb, and trichothecenes at 0.4 ppb against a separate cutoff of 0.2 ppb. Both exceeded their thresholds; destructive testing of the building found no water damage or significant fungal growth. The agency does not recommend biologic testing of people who work or live in water-damaged buildings, and the toxicology statement adds that antibody testing is not an accepted exposure measure.

The trial base, stated at its tier

A 2024 review sympathetic to the framework found the Shoemaker Protocol described in 11 of the 13 articles it identified, with minimal peer-reviewed publication from other groups; the randomized base is two cholestyramine trials of 8 and 13 subjects. In the primary trial, 7 randomized to drug improved, 6 on placebo did not until they crossed over, and all relapsed on building reexposure without the drug. That rechallenge was unblinded, and no mycotoxin was measured in any participant, so the result speaks to a bile acid sequestrant rather than to demonstrated toxin clearance.

The single independent replication compared 28 exposed individuals with 30 controls. The handheld contrast chart did not separate the groups; digital contrast sensitivity testing reached 100% sensitivity at 60-80% specificity. Exposure status was assigned from clinical signs with no exposure biomarker, which leaves circularity hard to exclude. Mechanism studies deserve their weight here without apology: trials exclude exactly the patient with polypharmacy, disrupted sleep and a flooded basement, so absence of a trial is a design fact, not a refutation.

Where the evidence is strongest: removing the exposure

The best controlled human data concern remediation. A Cochrane review pooling 12 studies and 8,028 participants found repairs reduced adult wheeze (odds ratio 0.64) and rhinitis (odds ratio 0.57), graded moderate quality, with no difference in children’s asthma days against information alone and no gut outcome in any included study. Occupational medicine and the European guideline, both skeptical of the diagnosis, hold that indoor mold growth should not be tolerated. The defensible plan is remediation, a period living away from the building, and dated symptom tracking.

The drivers under a stalled patient usually stack three deep. Barrier injury at the gut wall, the first brain in the book’s frame, is supported by mycotoxin data from cell, tissue and animal models. Immune activation is established for the allergic and infectious syndromes. The third is structural: in a 1989 survey of 597 households, mold growth appeared in 45.9% of dwellings, and repair falls to whoever owns the building rather than whoever breathes in it.

Documentation and where Measura fits

Stress is not a finding; it records the point at which the workup ended. A defensible chart carries the exposure history with dates, the location-dependent symptom pattern, the non-mold causes excluded, and objective function measures that can be repeated after the building is repaired. That structure belongs in the annual wellness visit and in standing orders with explicit selection criteria rather than in an unvalidated assay.

Measura’s role is host function, not exposure. Laboratory panels address alternative explanations for incomplete recovery, including the metabolic terrain and metaflammation. Cardiac autonomic reflex tests and heart rate variability quantify autonomic regulation when fatigue or orthostatic complaints dominate. Cognitive assessment documents cognition when concentration complaints are prominent and pairs with fall prevention workflows. None of these attributes a symptom to a building. Measured before remediation and repeated after, they turn the patient’s away-better observation into a documented n-of-1 comparison. The graded primary studies are in the book companion.

Frequently asked questions

References

• Bush, R. K., Portnoy, J. M., Saxon, A., Terr, A. I., & Wood, R. A. (2006). The medical effects of mold exposure. The Journal of Allergy and Clinical Immunology, 117(2), 326-333. https://doi.org/10.1016/j.jaci.2005.12.001
• Leikin, J., Holland, M. G., Kurt, T. L., McKay, C. A., & Stolbach, A. I. (American College of Medical Toxicology). (2025). ACMT position statement: Medical toxicology considerations in the diagnosis and treatment of patients with concerns about mold-related inhalation exposures. https://www.acmt.net/wp-content/uploads/2025/08/PS_250813_ACMT-Position-Statement-Mold-Related-Inhalation-Exposures.pdf
• Kawamoto, M., & Page, E. (2015). Notes from the field: Use of unvalidated urine mycotoxin tests for the clinical diagnosis of illness — United States, 2014. MMWR. Morbidity and Mortality Weekly Report, 64(6), 157-158. https://pubmed.ncbi.nlm.nih.gov/25695323/
• Catania, A., Airaghi, L., Garofalo, L., Cutuli, M., & Lipton, J. M. (1998). The neuropeptide alpha-MSH in HIV infection and other disorders in humans. Annals of the New York Academy of Sciences, 840, 848-856. https://doi.org/10.1111/j.1749-6632.1998.tb09622.x
• Dooley, M., Vukelic, A., & Jim, L. (2024). Chronic inflammatory response syndrome: a review of the evidence of clinical efficacy of treatment. Annals of Medicine and Surgery (2012), 86(12), 7248-7254. https://doi.org/10.1097/MS9.0000000000002718
• Shoemaker, R. C., & House, D. E. (2006). Sick building syndrome (SBS) and exposure to water-damaged buildings: time series study, clinical trial and mechanisms. Neurotoxicology and Teratology, 28(5), 573-588. https://doi.org/10.1016/j.ntt.2006.07.003
• Jimenez-Barbosa, I. A., Di Lizio, S., Ahn, S. B., Heng, B., Kim, J., Watson, A. J., & Khuu, S. K. (2026). Assessment of visual contrast sensitivity in biotoxin-exposed individuals using four testing methods. Annals of Medicine, 58(1), 2646821. https://doi.org/10.1080/07853890.2026.2646821
• Sauni, R., Verbeek, J. H., Uitti, J., Jauhiainen, M., Kreiss, K., & Sigsgaard, T. (2015). Remediating buildings damaged by dampness and mould for preventing or reducing respiratory tract symptoms, infections and asthma. Cochrane Database of Systematic Reviews, 2015(2), CD007897. https://doi.org/10.1002/14651858.CD007897.pub3
• Platt, S. D., Martin, C. J., Hunt, S. M., & Lewis, C. W. (1989). Damp housing, mould growth, and symptomatic health state. BMJ (Clinical Research Ed.), 298(6689), 1673-1678. https://doi.org/10.1136/bmj.298.6689.1673

Related reading

• Intestinal Methanogen Overgrowth: A Measurement-First Workup
• SIBO Recurrence Rate: Screening the Host After the Kill
• Laboratory Panels

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed September 12, 2026.